Abstract 306P
Background
Optimal adjuvant treatment for stage IA uterine papillary serous (UPSC) or clear cell carcinomas (UCCC) remains unknown. Options include no adjuvant treatment or systemic chemotherapy, Pelvic RT and Vaginal brachytherapy alone or in combination. These subtypes represent an infrequent set of patients, and hence there is lack of randomized trial data to guide optimal management. The aim of this study was to evaluate treatment patterns and relapse characteristics in this uncommon subtype based on the retrospective data from a single centre.
Methods
Clinicopathologic data, treatment patterns and relapse characteristics were retrospectively collected on patients of UPSC and UCCC treated between January 2014 and December 2018. Adjuvant treatment modalities used and their impact on relapse rates was analysed.
Results
We identified 21 patients who had undergone hysterectomy with bilateral salpingo-oophorectomy and were found to have stage 1A papillary serous or clear cell endometrial carcinoma. Nearly all patients (n-18, 85%) also underwent extended lymph node dissection of pelvic and para-aortic lymph nodes.
Median age at diagnosis was 61 years. Eighteen patients had uterine papillary serous carcinoma and three patients had clear cell histology. Eleven patients (52%) received systemic chemotherapy (six cycles of Paclitaxel and Carboplatin) with RT. and two patients received EBRT with or without VBT. Eight patients had no adjuvant treatment. At a median follow-up thirty months (range 6-63 months), six patient had experienced recurrences (28%). Nearly all the recurrences (n = 4) were in patients who received no adjuvant therapy with a relapse rate of 50% (4/8) in this subset. Four recurrences were distant metastasis while two were loco regional. At the time of last follow up, three patients with relapse had succumbed to their disease.
Conclusions
UPSC and UCCC are a distinct subtype of endometrial cancer and associated with an aggressive phenotype and high relapse rate even in patients with early stage. Systemic chemotherapy and Pelvic RT alone or in combination should always be considered in this group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract